Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00735449 · ClinicalTrials.gov registry record · Phase 4
Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects
A Phase 4 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 204
- Enrollment target
NCT00735449 is a Phase 4 study that has completed, run by Allergan. The registered enrollment target is 204 participants.
The verdict
NCT00735449, a Phase 4 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 204 participants
- Enrollment target
Study Summary
Efficacy and safety evaluation of Combigan with timolol when each is used as adjunctive therapy to Xalatan in subjects with glaucoma or ocular hypertension.
Interventions
- DRUG latanoprost 0.005%
- DRUG Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%
- DRUG timolol maleate 0.5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00735449
The ClinicalTrials.gov registry entry for NCT00735449 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which latanoprost 0.005% is the first listed.
NCT00735449 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00735449 about?
NCT00735449 is a clinical study titled "Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects". Efficacy and safety evaluation of Combigan with timolol when each is used as adjunctive therapy to Xalatan in subjects with glaucoma or ocular hypertension.
What is the current status of trial NCT00735449?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 204 participants. The study started on 2008-07. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00735449?
The interventions under investigation include: latanoprost 0.005% (DRUG), Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% (DRUG), timolol maleate 0.5% (DRUG).
Who is sponsoring clinical trial NCT00735449?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.